This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Nov. 8, 2012

Home   Find a Practitioner   Lectures   Conferences   Bookstore   Contact Us    



ICIM VIDEO

Video
Conrad Maulfair, DO, and the practice of chelation

Video
ICIM's Saving a Million Hearts Workshop

For copies of the video recording of on Flash drive contact Wendy at wendy@icimed.com

For a collection of 21 YouTube videos about using chelation for heart disease, please visit ICIM's YouTube channel


ICIM EVENTS

Yin/Yang: The Marriage Between Conventional and Innovative Medicine: March 14-18, Washington Marriott, Washington, D.C., Program Chair Conrad Maulfair, DO

Treating the Impossible II:
Oct. 9-12, 2013, Renaissance Columbus Downtown Hotel, Program Chair Richard Mason, DO


 
Special Issue on the Trial To Assess Chelation Therapy


Major study positive on chelation therapy
ICIM    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Chelation therapy for heart and vascular disease is an exciting but controversial alternative therapy that has been shown to be safe and statistically effective by the Trial to Assess Chelation Therapy. TACT is a seven-year study funded by the NIH and carried out by university cardiologists and experienced chelation physicians from around the United States and Canada. More

Fox News interview with chelation doctor Elizabeth Vaughan, MD
ICIM    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Dr. Elizabeth Vaughan provides chelation therapy to her patients and discusses the findings of the NIH-sponsored Trial to Assess Chelation Therapy with Fox News 8 in Greensboro, N.C. More

NIH trial gives surprising boost to chelation therapy
Forbes    Share    Share on FacebookTwitterShare on LinkedinE-mail article
With a result that is likely to surprise and baffle much of the mainstream medical community, a large NIH-sponsored trial has turned up the first substantial evidence in support of chelation therapy for patients with coronary disease. Known as Trial to Assess Chelation Therapy, the highly controversial trial was presented Nov. 4 at the American Heart Association by Dr. Gervasio Lamas. More

See related article: Response to the Forbes article by Bruce Dooley, MD


MeriCathW Winged Catheter
The MeriCathW Winged Catheters are high quality, sharp, and most importantly cost effective. We have spent many years researching and evaluating prototypes to offer professional healthcare providers a competitively priced excellent quality product.
Introductory Pricing:
1-3 Boxes $39.00, 4+ Boxes $37.00
Call toll free 1-800-421-9657


A timeline for EDTA chelation therapy and cardiovascular disease
Terry Chappell, John Trowbridge and Michael Schachter    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Chelation, from the Greek word "chele" meaning claw, implies that an organic molecule binds a cation — charged mineral — in a pincer-like fashion, forming a heterocyclic ring structure. The most widely accepted use of chelation therapy is for the removal of toxic minerals such as lead from the body. A more controversial indication, discovered serendipitously during treatment of patients suffering with lead toxicity, involving the use of the chelating agent disodium ethylene diaminetetraacetic acid, is in the treatment of all forms of atherosclerotic cardiovascular disease. More

Answering the tough questions: Handling negative media
Aaron Chappell Deckert, MSOD    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Handling the distress of negative criticism can be challenging, scary and overwhelming — whether from the media, a determined patient or a disgruntled employee. This type of interaction is an invitation to enter drama and that is rarely productive for either party. It is can also be opportunity to shine, to set yourself apart and to demonstrate that you are trustworthy, knowledgeable and consistent. More

Questions and answers: The NIH Trial of EDTA chelation therapy for coronary heart disease
National Heart Lung and Blood Institute    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Preliminary results from the Trial to Assess Chelation Therapy were presented Nov. 4 at the American Heart Association Scientific Sessions. The questions and answers provide information on the purpose of the study, what EDTA chelation is and about coronary heart disease in general. More

ICIM's Advanced Metal Toxicology Course in Washington, DC: Speakers and schedule
ICIM    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Three years ago, when we asked Richard Plumb, D.O., to be the program chairman of our Advanced Metal Toxicology Course, he said, "I'm not an expert; all I know is what I want to learn." This made him perfect for the job. Now, Rick has done it again with a fantastic lineup of new lectures to advance our practice of chelation therapy. This is Rick's dream list, and while not all of them are confirmed, you can bet he'll bring down the house with new ideas and expert reviews. More


Bobbie and Terry Chappell attended the American Heart Association meeting in Los Angeles to witness the TACT trial announcement. They were joined by other ICIM members Ted Rozema, M.D.; James Carter, M.D.; and Tammy Born, D.O.


Philosophy and history of science: Questioning statistics
Richard R. Mason, D.O.    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Evolution of predicting future outcomes in the scientific world have depended on keen observation and the use of the mathematical sciences of statistics and probability. With the advances of using computers to generate the "answers" that modern man is becoming reliant on to evolve provision of improvement of scientific understandings, much inquiry should be applied to the principles that plague this effort. More

The Chelation Interviews
ICIM    Share    Share on FacebookTwitterShare on LinkedinE-mail article
John Parks Trowbridge, M.D., FACAM, has practiced chelation therapy for almost 30 years at his Houston suburban practice, Life Celebrating Health. Certified as a specialist since 1985, he presently serves as secretary to the American Board of Clinical Metal Toxicology. Trowbridge has served in leadership positions with various professional organizations. He has produced more than 50 hours of CDs and DVDs on various topics in integrative medicine. His most popular book, Bantam's "The Yeast Syndrome," is now available in e-book format. For copies of his CDs and DVDs, dial 1-800-FIX-PAIN. More

3 Papers on New Chelator NBMI
Boyd E. Haley, Ph.D.    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Our new chelator, called NBMI for research purposes, has been tested and shown effective at preventing the "leakage" of aortic endothelial cell and intestinal epithelial cell membranes on exposure to mercury, methyl mercury and thimerosal. Regarding the cardiovascular issue, NBMI was very effective at preventing the abnormal biochemistry and oxidative stress associated with the development of atherosclerotic plaques that was induced by these mercury compounds and an organic toxin called bleomycin. Here are three research articles on NBMI:


 

ICIM: Your Between Conference Connection
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ronnie Richard, Content Editor, 469.420.2682   
Contribute news

This edition of ICIM: Your Between Conference Connection was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Nov. 8, 2012
Nov. 2, 2012
Oct. 26, 2012
Oct. 19, 2012



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063